I've got a busy schedule of events coming up over the next few months. First, if you're headed to Chicago for BIO later this month, I hope you'll come by my executive breakfast. The big challenge in drug development now is figuring out how to do much faster, more efficient clinical drug programs. And I'll be challenging some of the top R&D executives in the industry to explain the strategies they've chosen to put their companies in the lead of this revolution.
Briggs Morrison, EVP, Global Medicines Development, AstraZeneca ($AZN); Martin Fitchet, chief operating officer and heart disease expert for the global Johnson & Johnson ($JNJ) Pharmaceutical Research & Development organization; José-Carlos Gutiérrez-Ramos, SVP and head of BioTherapeutics R&D at Pfizer ($PFE); and Perry Nisen, SVP of science and innovation at GlaxoSmithKline ($GSK), will be on hand to discuss this with me on April 23 at 7:30 a.m. You can register here.
Next week I have a webinar scheduled for 2 p.m. on April 18. My panel will offer up some ideas on the most effective methods for designing a clinical program for rare disease drugs, one of the hottest fields in the industry right now. Dr. Gerry Cox, VP of clinical development for Rare Diseases at Genzyme; J. Russell Teagarden, senior VP of medical and scientific affairs at the National Organization for Rare Disorders; Giles Campion, chief medical officer and senior VP of R&D at Prosensa; and Todd Stutzman, director of pharmaceutics at Catalent, will be on hand to offer their ideas. This one is free, so I hope you can join us online. Register here.
Skipping ahead a month, I'm headed down to Nutley, NJ, on the morning of May 10 to meet with Roche's ($RHHBY) translational medicine group, which will soon be moving to new digs in Manhattan. They asked me to drop by that morning to discuss the changes underway in the field. I'll be doing a presentation on some of the most noteworthy translational research programs I've been seeing over the last couple of years as Big Pharma restructured its pipelines.
Then it's off to London. I'll be moderating a panel at BioTrinity in the U.K. on May 16 covering "Innovative Financing and Deferred Consideration: Essential Parts of Deal Terms?" Tim Herpin, VP of strategic partnering and business development at AstraZeneca's Oncology and STL unit; David Colpman, global head of business development at Shire Pharmaceuticals ($SHPG); Judith Hills, vice president of corporate business development at Ipsen Biopharm ($IPN); Stewart Kay, director of transactions at GlaxoSmithKline; and Simon Dew, vice president of business development and early phase commercial development at Astellas, will be joining me. Check it out here.